Skip to main content
European Commission logo print header

A Novel Rapid Nucleic Acid Isolation Microchip Intergrated in the FASTGENE PCR Microfluidics Device for Point of Care Diagnosis of Infectious Diseases

Project description

Accurate pathogen detection in minutes

Polymerase chain reaction (PCR) has revolutionised the field of molecular biology and has found numerous applications including the detection of infectious microorganisms and viruses. Although it is a very sensitive method, it is time-consuming and laborious. The scope of the EU-funded NORAMID SE project is to develop a microchip for isolating nucleic acid DNA from biological samples at the point of care. This will be integrated into a microfluidics device for the diagnosis of infectious diseases with high accuracy. With results ready within 20 minutes, NORAMID SE will aid prompt pathogen detection.


The catastrophic impact of infectious diseases including the recent coronavirus (covid-19) pandemic on global health cannot be over emphasized. Polymerase chain reaction (PCR) based techniques are the most sensitive and reliable diagnostic tools for infectious diseases but are time-consuming and labour-intensive. This project aims to develop a simple, rapid and cost-effective novel nucleic acid (NA) isolation microchip and integrate it in the FASTGENE PCR microfluidics device for point of care (POC) diagnosis of infectious diseases. The project will exploit the competence of the experience researcher (ER) on the theoretical and practical knowledge of medical biotechnology and molecular epidemiology while implementing the expertise of BforCure team in microfluidics design to develop this new microchip. The ER will develop a new NA isolation microchip based on silica gel solid phase extraction system and integrate it in the FASTGENE PCR microfluidics device of BforCure to become a closed system device that automatically extracts NA and amplifies it to detect infectious diseases. After the design and production, the device will be tested for its efficiency. Once satisfied, positive control bacteria and viral samples will be used to assess the performance of the device and the results will be compared with that of standard commercially available NA extraction and PCR kits. The device is expected to have high sensitive compared to other microfluidics devices, reliable and can detect pathogens in less than 20 minutes. A patent will be secured for the product while the findings of the research will be made public and commercialized. This novel device will be suitable for POC diagnosis to promptly detect and manage infectious diseases. This project will develop the ER’s potential to transform research ideas to products and build up his industrial experience. It will make the ER gain expertise in the design and fabrication of microfluidics tools and develop his entrepreneuri



Net EU contribution
€ 196 707,84
14 rue de la beaune
93100 Montreuil

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Ile-de-France Ile-de-France Seine-Saint-Denis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00